Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
REDWOOD CITY, Calif. , April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer,
Toggle Summary Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference
REDWOOD CITY, Calif. , March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle Summary Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S.
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
REDWOOD CITY, Calif. , March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the
Toggle Summary Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases
REDWOOD CITY, Calif. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has signed a collaboration agreement with Vanderbilt
Toggle Summary Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome
Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints REDWOOD CITY, Calif. , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
Toggle Summary Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome
Webinar on Thursday, February 4, at 12:00 PM ET REDWOOD CITY, Calif. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a
Toggle Summary Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
REDWOOD CITY, Calif. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present a corporate overview at the H.C.
Toggle Summary Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Soleno intends to submit plans to FDA to conduct further analyses of clinical data from completed and ongoing studies of DCCR, together with external, natural history studies REDWOOD CITY, Calif. , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
REDWOOD CITY, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third